Pharma News Intelligence March 10, 2020
Gene therapy, cell therapy, and other regenerative medicines raised millions in 2019, and experts expect dollars to increase as adoption soars.
Globally, companies manufacturing gene therapy, cell therapy, and other regenerative medicines raised nearly $10 billion in 2019, the second-highest year on record, according to a recent analysis from the Alliance for Regenerative Medicine (ARM).
ARM released its 2019 Annual Report and Sector Year in Review last week, highlighting the organization’s key priorities and initiatives, as well as offering a deeper look into trends and metrics for cell therapy, gene therapy, and tissue engineering sectors.
Using data sourced from ARM’s data partner, Informa, researchers uncovered that venture financing made up more than $4 billion in global financings, which is a...
Today's Sponsors
Today's Sponsor